Area of research
Hematology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, and Acute Lymphoblastic Leukemia research.
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment Efficacy.
Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma
Intrathecal chemotherapy for ciltacabtagene autoleucel–associated movement and neurocognitive toxicity
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis
Late complications and long-term care of adult CAR T-cell patients
Optimization of older adults by a geriatric assessment–guided multidisciplinary clinic before CAR T-cell therapy
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists.
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma
KI‐67 PROLIFERATION PATTERNS ARE PREDICTIVE OF EARLY PROGRESSION AND INFERIOR OUTCOMES IN GRADE 1–2 FOLLICULAR LYMPHOMA
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome